Haftalık karboplatin/paklitaksel ile kemoradyoterapi inoperabl evre ııı küçük hücreli dışı akciğer kanserinde uygun bir seçenek olabilir. tek merkez deneyimi

Amaç: Eşzamanlı kemoradyoterapi (KRT) cerrahi tedaviye uygun olmayan lokal ileri evre Küçük Hücreli Dışı Akciğer Kanseri (KHDAK) tanılı hastalar için standart bir tedavi yöntemidir. KRT için optimal bir kemoterapi rejimi tanımlanmamıştır. Bu çalışmada, karboplatin  (AUC 2)  ve paklitaksel (80 mg / m2) ile kombine KRT tedavisinin etkinliği ve toksisitesini araştırdık.Gereç ve Yöntem: Bu çalışma hastane bazlı retrospektif gözlemsel vaka seri çalışması olarak tasarlanmıştır. İnoperabl evre III KHDAK'li toplam 40 hasta haftalık karboplatin-paklitaksel ile eş zamanlı kemoradyoterapi ile tedavi edildi.Bulgular: En sık görülen histopatoloji, 18 hastada (% 45) teşhis edilen adenokarsinomdu. 12 hasta (% 30) evre IIIA ve 28 hasta (% 70)  evre IIIB idi. Ortanca takip süresi 22.5 ay idi [% 95 (CI), 2.9-72.2]. Medyan hastalıksız sağkalım (DFS) ve genel sağkalım (OS) 22.5 ay (% 95 CI, 18.1–27.0) ve 53.5 ay (% 95 CI, 23.5-82.8) idi. Hastaların 8'inde (% 20) ve 5'inde (% 12.5) sırasıyla  grade 3-4 hematolojik ve non-hematolojik toksisite izlendi.Sonuç: Bu çalışma, haftalık karboplatin-paklitaksel ile KRT'nin literatürdeki vakalara benzer sonuçlar verdiğini ve inoperable evre III KHDAK' de KRT sırasında düşük dereceli 3-4 derece toksisite ile uygulanabilir olduğunu gösterdi.

Concurrent chemoradiotherapy with weekly carboplatin and paclitaxel may be a feasible option in inoperable stage III non-small cell lung cancer: A single center experience

Purpose:Concurrent chemoradiotherapy (CCRT) is a standard treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC). An optimal chemotherapy regimen with concurrent thoracic radiotherapy is not known. In this study, we investigated the efficacy and toxicity of CCRT with carboplatin [area under curve (AUC) 2] and paclitaxel (80 mg/m2) during CCRT.Materials and Methods:We performed a retrospective survival analysis using medical records of 40 patients with inoperable stage III NSCLC that were treated with concurrent chemoradiotherapy with carboplatin-paclitaxel (AUC 2, 60 mg/m2).Results:The median patient age was 62 years (range: 40–77 years) and 36 patients (90%) were men. The European Cooperative Oncology Group (ECOG) performance score was 0 in 23 patients (57.5%). The most common histopathology was adenocarcinoma, which was diagnosed in 18 patients (45%). There were 12 stage IIIA patients (30%) and 28 stage IIIB patients (70%). The median follow-up time was 22.5 months [95% confidence interval (CI), 2.9–72.2]. Median disease-free survival (DFS) and overall survival (OS) were 22.5 months (95% CI, 18.1–27.0) and 53.5 months (95% CI, 23.5–82.8). Grade 3-4 hematological and non-hematological toxicities were seen in 8 (20%) and 5 (12.5%) patients, respectively.Conclusion:This study showed that CCRT with weekly carboplatin-paclitaxel provides similar outcomes to cases in the literature and the regimen seems to be feasible with a low rate of grade 3-4 toxicity during CCRT of non-operable stage III NSCLC.

___

  • 1. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604-8.
  • 2. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non–small-cell lung cancer. J ClinOncol. 1999;17:2692–9
  • 3. Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S et al: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J. Natl Cancer Inst. 2011;103:1452–60
  • 4. Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002;20:3454-60.
  • 5. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23:5883-91.
  • 6. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940-5.
  • 7. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87:198-205.
  • 8. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692-9.
  • 9. Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol 2017;28:777-83.
  • 10. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B et al. PROCLAIM: Randomized phase III Trial of pemetrexed-cisplatin or etoposidecisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34:953-62.
Cukurova Medical Journal-Cover
  • ISSN: 2602-3032
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1976
  • Yayıncı: Çukurova Üniversitesi Tıp Fakültesi